Biophytis Unveils Promising Preclinical Data for Obesity Treatment

Biophytis SA ( (FR:ALBPS) ) has issued an update.

Biophytis SA has announced new preclinical data showcasing the potential of its drug candidate BIO101, in combination with GLP-1, to restore muscle strength and mobility in obese patients. The study, presented at an international conference, demonstrated significant improvements in mobility and grip strength in obese mice, highlighting the potential of this combination therapy to address a major unmet medical need for obesity-related muscle decline. This development positions Biophytis as a pioneer in the field, aiming to enhance treatment options for the nearly one billion individuals affected by obesity worldwide.

More about Biophytis SA

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its main drug candidate, BIO101, is being developed for muscle diseases like sarcopenia and metabolic diseases such as obesity. The company is based in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil, and is listed on Euronext Growth Paris and the OTC market.

YTD Price Performance: -16.00%

Average Trading Volume: 18,486

Technical Sentiment Signal: Buy

Current Market Cap: €4.3M

Find detailed analytics on ALBPS stock on TipRanks’ Stock Analysis page.